Literature DB >> 7723460

Controlling for confounding by indication for treatment. Are administrative data equivalent to clinical data?

R M Poses1, W R Smith, D K McClish, M Anthony.   

Abstract

There has been controversy about whether confounding by indication for treatment--that is, owing to physicians' conscious efforts to base treatment decisions on patients' pretreatment prognoses--makes nonrandomized, observational comparisons of treatments invalid. Some now believe evidence from studies of practice variation means that physicians' treatment decisions have little relationship to patients' prognostic clinical characteristics. They therefore believe that patients who receive different treatments should vary little in their baseline prognoses, and multivariable statistical methods should easily be able to adjust for any resultant confounding, even when analyses are restricted to administrative rather than clinical data. The objective of this study is to determine whether adjusting for variables found in administrative data sets produces the same results as does adjusting for clinical variables. Data were reanalyzed from a previously enrolled prospective sequential cohort of 227 hospitalized patients with suspected bacteremia who had blood cultures. The treatment under study was aminoglycoside therapy given empirically, that is, before blood culture results were known. The outcome of interest was death during hospitalization. Univariable analyses suggest that empiric aminoglycoside therapy had a positive association with mortality, by univarible logistic regression, odds ratio (OR = 3.1 (95% confidence interval = [1.6, 5.8]). Few administrative variables had univariable associations with aminoglycoside use or death. Multivariable analyses that controlled for them still suggest that aminoglycosides increased mortality; for example, in one model, adjusted OR = 3.2 (1.6, 6.5). Many clinical variables were strongly associated with aminoglycoside use or death. Analyses that controlled for them suggested that empiric aminoglycosides did not increase mortality; for example, in one model, adjusted OR = 1.2 (0.55, 2.7.) Results of adjustment for confounding using administrative data disagreed with the results of adjustment using clinical data. It is concluded that nonrandomized, observational outcome studies that fail to control for prognostic differences between patients receiving different treatments may not always be valid.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7723460

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  12 in total

Review 1.  Use of routine healthcare data in safe and cost-effective drug use.

Authors:  C J Currie; T M MacDonald
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

2.  Improved comorbidity adjustment for predicting mortality in Medicare populations.

Authors:  Sebastian Schneeweiss; Philip S Wang; Jerry Avorn; Robert J Glynn
Journal:  Health Serv Res       Date:  2003-08       Impact factor: 3.402

3.  Heterogeneity in healthy aging.

Authors:  David J Lowsky; S Jay Olshansky; Jay Bhattacharya; Dana P Goldman
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2013-11-17       Impact factor: 6.053

4.  GPs' antibiotic prescription patterns for respiratory tract infections--still room for improvement.

Authors:  Svein Gjelstad; Ingvild Dalen; Morten Lindbaek
Journal:  Scand J Prim Health Care       Date:  2009       Impact factor: 2.581

5.  Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.

Authors:  José María Martínez-Ortega; Francisco Diaz-Atienza; Luis Gutiérrez-Rojas; Dolores Jurado; Manuel Gurpegui
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-09-17       Impact factor: 4.785

Review 6.  Difficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studies.

Authors:  Kristen A Stafford; Mallory Boutin; Scott R Evans; Anthony D Harris
Journal:  Clin Infect Dis       Date:  2014-06-30       Impact factor: 9.079

7.  Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry.

Authors:  Andrew J Karter; Howard H Moffet; Jennifer Liu; Melissa M Parker; Ameena T Ahmed; Assiamira Ferrara; Joe V Selby
Journal:  Am J Manag Care       Date:  2005-04       Impact factor: 2.229

8.  Glycemic response to newly initiated diabetes therapies.

Authors:  Andrew J Karter; Howard H Moffet; Jennifer Liu; Melissa M Parker; Ameena T Ahmed; Alan S Go; Joe V Selby
Journal:  Am J Manag Care       Date:  2007-11       Impact factor: 2.229

9.  Emulating a Novel Clinical Trial Using Existing Observational Data. Predicting Results of the PreVent Study.

Authors:  Andrew J Admon; John P Donnelly; Jonathan D Casey; David R Janz; Derek W Russell; Aaron M Joffe; Derek J Vonderhaar; Kevin M Dischert; Susan B Stempek; James M Dargin; Todd W Rice; Theodore J Iwashyna; Matthew W Semler
Journal:  Ann Am Thorac Soc       Date:  2019-08

10.  Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data.

Authors:  Sebastian Schneeweiss; Philip S Wang; Jerry Avorn; Malcolm Maclure; Raia Levin; Robert J Glynn
Journal:  J Gen Intern Med       Date:  2004-05       Impact factor: 6.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.